Coeptis Therapeutics, Inc. (COEP)

NASDAQ: COEP · IEX Real-Time Price · USD
0.541
-0.039 (-6.71%)
At close: Mar 1, 2024, 4:00 PM
0.530
-0.011 (-2.03%)
After-hours: Mar 1, 2024, 7:46 PM EST
-6.71%
Market Cap 18.45M
Revenue (ttm) n/a
Net Income (ttm) -20.19M
Shares Out 34.11M
EPS (ttm) -2.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 412,991
Open 0.589
Previous Close 0.580
Day's Range 0.516 - 0.589
52-Week Range 0.325 - 2.190
Beta -0.84
Analysts Strong Buy
Price Target 5.67 (+948.06%)
Earnings Date Mar 27, 2024

About COEP

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screen... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol COEP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for COEP stock is "Strong Buy." The 12-month stock price forecast is $5.67, which is an increase of 948.06% from the latest price.

Price Target
$5.67
(948.06% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune di...

6 days ago - PRNewsWire

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Novel NK cell therapy approach is designed to bolster and replenish the immune system during severe viral infection, which can severely reduce immune cells leading to hospitalization and death WEXFORD...

25 days ago - PRNewsWire

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

WEXFORD, Pa. , Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms fo...

2 months ago - PRNewsWire

Coeptis Therapeutics to Present at the Emerging Growth Conference

WEXFORD, Pa. , Dec. 4, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms fo...

3 months ago - PRNewsWire

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Poster presentation describes the development of SNAP CAR platform technology as a "universal" CAR therapy with the potential to target multiple antigens through combinatorial use of different adaptor...

4 months ago - PRNewsWire

Coeptis Therapeutics Announces $2 Million Private Placement

WEXFORD, Pa. , Oct. 24, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms f...

4 months ago - PRNewsWire

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Coeptis now has exclusive rights to SNAP-CAR NK and SNAP-CAR T-Cell technology platforms WEXFORD, Pa. , Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "...

5 months ago - PRNewsWire

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

WEXFORD, Pa. , Oct. 9, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms fo...

5 months ago - PRNewsWire

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Poster to be presented by research team from University of Pittsburgh, led by Jason Lohmueller, Ph.D., Assistant Professor of Immunology WEXFORD, Pa.

5 months ago - PRNewsWire

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

WEXFORD, Pa. , Sept. 27, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms ...

5 months ago - PRNewsWire

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

DVX201, a first-ever allogeneic, cord-blood derived, natural killer (NK) cell therapy, has been administered to 16 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxi...

6 months ago - PRNewsWire

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Grants totaling approximately $3.5 million will support Deverra's CAR-NK and engineered myeloid cell programs in hematologic malignancies and solid tumors WEXFORD, Pa. , Sept. 11, 2023 /PRNewswire/ --...

6 months ago - PRNewsWire

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa. , Aug. 30, 2023 /PRNewswire/ --...

6 months ago - PRNewsWire

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infectio...

7 months ago - PRNewsWire

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

513(g) request will help initiate dialogue with FDA and guide regulatory pathway WEXFORD, Pa. , Aug. 1, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Compa...

7 months ago - PRNewsWire

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

WEXFORD, Pa. , June 16, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms f...

9 months ago - PRNewsWire

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

WEXFORD, Pa. , June 14, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms f...

9 months ago - PRNewsWire

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

Trading to commence effective with the open of business on June 13, 2023 WEXFORD, Pa. , June 9, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a ...

9 months ago - PRNewsWire

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa. , May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Hold...

10 months ago - PRNewsWire

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

SNAP-CAR represents a major advance potentially expanding the targeting capabilities of chimeric antigen receptor (CAR) T cells for various cancers and other indications WEXFORD, Pa. , May 10, 2023 /P...

10 months ago - PRNewsWire

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a bi...

11 months ago - PRNewsWire

Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies

Potential acquisition of VyGen-Bio would strengthen Coeptis' oncology pipeline by obtaining exclusive, worldwide ownership rights to GEAR™ Platform and companion diagnostic technologies WEXFORD, Pa. ,...

1 year ago - PRNewsWire

Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine

SNAP-CAR recognized in research detailing advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility WEXFORD, Pa. , March 21, 2023 /PRNewswir...

1 year ago - PRNewsWire

Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling

Coeptis strengthens measures to protect shareholder interests through ShareIntel's investigation and due diligence services WEXFORD, Pa. , Feb. 7, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, I...

1 year ago - PRNewsWire

Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program

Coeptis to collaborate with IQVIA, a global contract research organization, to identify target indications and initiate IND-enabling activities for SNAP-CAR WEXFORD, Pa. , Nov. 22, 2022 /PRNewswire/ -...

Other symbols: IQV
1 year ago - PRNewsWire